Table 3 Incremental cost-effectiveness ratio of alternate treatment strategy relative to standard autologous ART treatment
Age | PGT-A | Donor ART | Social Oocytes |
|---|---|---|---|
Mean ICER (USD) | Mean ICER (USD) | Mean ICER (USD) | |
35 | 17,790 (−133,529 to 124,370) | 26,240 (20,964 to 34,639) | – |
36 | 7,997 (− 113,502 to 103,557) | 19,674 (16,377 to 242,56) | – |
37 | 3,282 (− 93,270 to 85,661) | 15,850 (13,665 to 18,757) | – |
38 | 250 (− 61,855 to 55,078) | 23,244 (19,920 to 28,036) | – |
39 | More effective and cost saving | 19,504 (17,056 to 22,758) | – |
40 | 17,976 (4742 to 127,836) | 17,732 (15,832 to 20,125) | More effective and cost saving |
41 | 21,256 (−66,525 to 168,998) | 13,422 (12,091 to 15,071) | More effective and cost saving |
42 | 5,269 (1926 to 13,031) | 12,189 (11,067 to 13,557) | More effective and cost saving |
43 | 1,947 (101 to 5,107) | 10,086 ( 9321 to10,990 ) | More effective and cost saving |
44 | 1,111 (− 366 to 3,513) | 9,918 ( 9,225 to 10,758to ) | More effective and cost saving |
45 | 2,246 (537 to 5,683) | 12,718 (11,899 to 13,900) | More effective and cost saving |